ARIAD to present preclinical data on ponatinib

ARIAD Pharmaceuticals announced the presentation of preclinical data on ponatinib at the American Association for Cancer Research Annual Meeting 2013, in Washington. The study, "Ponatinib, a pan-BCR-ABL inhibitor, potently inhibits key activating and drug-resistant KIT mutants found in GIST," shows that ponatinib inhibits activated and mutated forms of KIT, a clinically proven oncogenic driver found in approximately 80 percent of patients with gastrointestinal stromal tumors.

View Comments (0)